Horizon Therapeutics
stock plunged 18% early Tuesday on reports that the Federal Trade Commission is set to challenge
Amgen
$27.8 billion deal to buy the biotech company.
Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal
